Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 28

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 28
---
 dismissed prior to such ninetieth day, and (iv) the date on which, pursuant to or within the meaning of any bankruptcy
law, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for the benefit
of our creditors, or each, a Termination Event.

We do not have a right to
commence any sales of Depositary Shares to the Selling Shareholder under the Purchase Agreement until the time when all of the conditions
to our right to commence sales of Depositary Shares to the Selling Shareholder set forth in the Purchase Agreement have been satisfied,
or the Commencement Date, including the effectiveness of the registration statement of which this prospectus forms a part. Over the 36-month
period from and after the Commencement Date, we will generally have the right to control the timing and amount of any sales of our Depositary
Shares to the Selling Shareholder under the Purchase Agreement. Sales of our Depositary Shares, if any, to the Selling Shareholder under
the Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to
the Selling Shareholder all, some or none of the Depositary Shares that may be available for us to sell to the Selling Shareholder pursuant
to the Purchase Agreement. Accordingly, we cannot guarantee that we will be able to sell all of the Commitment Amount or how much in proceeds
we may obtain under the Purchase Agreement. If we cannot sell securities under the Committed Equity Financing, we may be required to utilize
more costly and time-consuming means of accessing the capital markets, which could have a material adverse effect on our liquidity and
cash position.

Because the purchase price
per Depositary Share to be paid by the Selling Shareholder for the Depositary Shares that we may elect to sell to the Selling Shareholder
under the Purchase Agreement, if any, will fluctuate based on the market prices of our Depositary Shares at the time we make such election,
it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of Depositary Shares that
we will sell to the Selling Shareholder under the Purchase Agreement, the purchase price per share that the Selling Shareholder will pay
for Depositary Shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those
purchases the Selling Shareholder under the Purchase Agreement.

We are registering